Treatment of refractory pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab): Five cases

References

• Nishifuji K., Amagai M., Kuwana M., Iwasaki T., Nishikawa T. Detection of antigen‐specific B cells in patients with pemphigus vulgaris by enzyme‐linked immunospot assay: Requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000; 114: 88–94
   PubMed Web of Science ®Google Scholar
• Herbst A., Bystryn J. C. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 422–7
   PubMed Web of Science ®Google Scholar
• Lin M. S., Swartz S. J., Lopez A., Ding X., Fernandez‐Vina M. A., Stastny P., et al. Development and characterization of desmoglein‐3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997; 99: 31–40
   PubMed Web of Science ®Google Scholar
• Arin M. J., Engert A., Krieg T., Hunzelmann N. Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620–5
   PubMed Web of Science ®Google Scholar
• Cooper H. L., Healy E., Theaker J. M., Friedmann P. S. Treatment of resistant pemphigus vulgaris with an anti‐CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol 2003; 28: 366–8
   PubMed Web of Science ®Google Scholar
• Amagai M., Karpati S., Prussick R., Klaus‐Kovtun V., Stanley J. R. Autoantibodies against the amino‐terminal cadherin‐like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90: 919–26
   PubMed Web of Science ®Google Scholar
• Smith M. R. Rituximab (monoclonal anti‐CD20 antibody): Mechanisms of action and resistance. Oncogene 2003; 22: 7359–68
   PubMed Web of Science ®Google Scholar
• Treon S. P., Anderson K. C. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27((6 suppl 12))79–85
   Google Scholar
• Belgi A. S., Azeez M., Hoyle C., Williams R. E. Response of pemphigus vulgaris to anti‐CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006; 31: 143
   PubMedGoogle Scholar
• Ratanatharathorn V., Carson E., Reynolds C., Ayash L. J., Levine J., Yanik G., et al. Anti‐CD20 chimeric monoclonal antibody treatment of refractory immune‐mediated thrombocytopenia in a patient with chronic graft‐versus‐host disease. Ann Intern Med 2000; 133: 275–9
   PubMed Web of Science ®Google Scholar
• Anolik J., Sanz I., Looney R. J. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003; 5: 350–6
   PubMedGoogle Scholar
• Taylor P. C. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 323–8
   PubMed Web of Science ®Google Scholar
• Quartier P., Brethon B., Philippet P., Landman‐Parker J., Le Deist F., Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511–13
   PubMed Web of Science ®Google Scholar
• Wylam M. E., Anderson P. M., Kuntz N. L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J Pediatr 2003; 143: 674–7
   PubMed Web of Science ®Google Scholar
• Wenzel J., Bauer R., Bieber T., Tuting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol 2005; 85: 185–6
   PubMedGoogle Scholar
• Espana A., Fernandez‐Galar M., Lloret P., Sanchez‐Ibarrola A., Panizo C. Long‐term complete remission of severe pemphigus vulgaris with monoclonal anti‐CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004; 50: 974–6
   PubMedGoogle Scholar
• Morrison L. H. Therapy of refractory pemphigus vulgaris with monoclonal anti‐CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817–19
   PubMed Web of Science ®Google Scholar
• Dupuy A., Viguier M., Bedane C., Cordoliani F., Blaise S., Aucouturier F., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti‐CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91–6
   PubMed Web of Science ®Google Scholar
• Herrmann G., Hunzelmann N., Engert A. Treatment of pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 602–3
   PubMedGoogle Scholar
• Schmidt E., Herzog S., Brocker E. B., Zillikens D., Goebeler M. Long‐standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005; 153: 449–51
   PubMed Web of Science ®Google Scholar
• Goebeler M., Herzog S., Brocker E. B., Zillikens D. Rapid response of treatment‐resistant pemphigus foliaceus to the anti‐CD20 antibody rituximab. Br J Dermatol 2003; 149: 899–901
   PubMedGoogle Scholar
• Kong H. H., Prose N. S., Ware R. E., Hall R. P., 3rd. Successful treatment of refractory childhood pemphgus vulgaris with anti‐CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005; 22: 461–4
   PubMed Web of Science ®Google Scholar
• Virgolini L., Marzocchi V. Anti‐CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: Report of a case. Haematologica 2003; 88: ELT24
   PubMedGoogle Scholar
• El Tal A. K., Posner M. R., Spigelman Z., Ahmed A. R. Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2006; 55: 449–59
   PubMed Web of Science ®Google Scholar
• Schmidt E., Hunzelmann N., Zillikens D., Brocker E. B., Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31: 503–8
   PubMed Web of Science ®Google Scholar
• Schadlow M. B., Anhalt G. J., Sinha A. A. Using rituximab (anti‐CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564–7
   PubMedGoogle Scholar
• Rossum M. M., Verhaegen N. T., Jonkman M. F., Mackenzie M. A., Koster A., Van Der Valk P. G., et al. Follicular non‐Hodgkin's lymphoma with refractory paraneoplastic pemphigus: Case report with review of novel treatment modalities. Leuk Lymphoma 2004; 45: 2327–32
   PubMed Web of Science ®Google Scholar